On January 27, 2026 BridGene Biosciences, Inc., a leader in the discovery and development of small molecule drugs for traditionally "hard-to-drug" targets, reported the recent completion of a $28 million Series B+ financing round. The round was led by Bayland Capital, with participation from GTJA Investment Group, Proxima Ventures, and existing investors Lapam Capital and Grains Valley Venture Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from the financing will be used to advance BGC-515, a covalent TEAD inhibitor for solid tumors, through ongoing clinical development and toward Phase 2. The funding will also support the company’s second program, expected to enter the clinic in 2027, and accelerate the development of additional programs in oncology and autoimmune diseases. In addition, the financing enhances BridGene’s capacity to expand strategic collaborations and further validate the broad applicability of its proprietary IMTAC chemoproteomic platform across oncology, immunology, and neurology.

"Our recent financing provides important resources to advance our lead program, BGC-515, a covalent TEAD inhibitor, through Phase 2 clinical development," said Ping Cao, Ph.D., CEO and co-founder of BridGene Biosciences. "This funding will also enable us to progress additional pipeline programs toward the clinic and further expand the reach of our IMTAC chemoproteomic platform through strategic collaborations, as we continue to translate our discoveries into transformative therapies for patients."

"We are excited to lead this financing round for BridGene Biosciences," said Yuexing Su, Founding Partner of Bayland Capital. "BridGene’s IMTAC platform represents a powerful and differentiated approach to drug discovery, enabling the company to discover small molecules against traditionally undruggable targets. With a growing pipeline led by the covalent TEAD inhibitor BGC-515 and multiple follow-on programs across oncology and autoimmune diseases, we believe BridGene is well positioned to deliver transformative therapies to patients and generate substantial value in the biopharmaceutical field."

(Press release, Bridgene Biosciences, JAN 27, 2026, View Source [SID1234662302])

On January 27, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, reported changes to the previously announced key dates relating to its proposed rights offering (the "Rights Offering"). Except as expressly amended herein, the terms of the Rights Offering remain unchanged. Assuming that the Rights Offering is fully subscribed, the Company will receive gross proceeds of $12 million, less expenses related to the Rights Offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Subscription Rights will be non-transferable and may only be exercised during the amended subscription period of Wednesday, February 11, 2026 through 5:00 p.m. Eastern Time on Friday, February 27, 2026, unless extended by AIM.

The amended calendar for the Rights Offering is now as follows:

February 9, 2026: Ownership Day – in order to be considered a stockholder of record on February 10, 2026, shares should be acquired by this date (open market purchases of Common Stock should be completed by February 9, 2026 to be considered a stockholder of record on the Record Date).
February 10, 2026: Record Date (5:00 p.m. Eastern Time)
February 11, 2026: Distribution Date; Subscription Period Begins
February 27, 2026: Subscription Period Ends 5:00 p.m. Eastern Time
The Rights Offering will include an over-subscription privilege which permits each holder of Subscription Rights that exercises such holder’s basic Subscription Right in full to purchase additional subscriptions (if any) that remain unsubscribed at the expiration of the Rights Offering. The availability of the over-subscription privilege will be subject to certain terms and restrictions set forth in the prospectus. If the aggregate subscriptions (basic subscriptions plus over-subscriptions) exceed the number of subscriptions offered in the Rights Offering, then the aggregate over-subscription amount will be pro-rated among the holders exercising their respective over-subscription privileges (in proportion to the number of subscriptions held after giving effect to all basic subscriptions).

Certain of AIM’s leadership have indicated to the Company on a non-binding basis that they intend to participate in the Rights Offering, including Board member and Chief Executive Officer Thomas K. Equels.

The Company intends to use the net proceeds from the exercise of subscriptions for general corporate purposes – including clinical trial expenses and manufacturing expenses associated with prospective Phase 2/3 pancreatic cancer trials – and allocate a portion of the net proceeds to repay, according to their terms, certain existing debt obligations.

The Rights Offering will expire at 5:00 p.m., Eastern Time, on Friday, February 27, 2026, unless it is extended or earlier terminated by the Company, If the Company elects to extend the Rights Offering, it will issue a press release announcing the extension no later than 9:00 a.m., Eastern Time, on the next business day after the most recently announced expiration date of the Rights Offering. The Company may extend the Rights Offering for additional periods in its sole discretion for any reason up to an additional 45 days. Once made, all exercises of subscriptions are irrevocable.

The Company expects that Broadridge Corporate Issuer Solutions, LLC, the information agent for the Rights Offering, will mail rights certificates and a copy of the prospectus for the Rights Offering to holders of record of Common Stock and Participating Securities as of the Record Date beginning on or about February 11, 2026. Holders of securities held in "street name" through a brokerage account, bank or other nominee will not receive physical rights certificates and must instruct their broker, bank or other nominee whether to exercise Subscription Rights on their behalf. For any questions or further information about the Rights Offering, please call Broadridge Corporate Issuer Solutions, LLC, the information agent for the Rights Offering, at (855) 793-5068 or via email at [email protected].

Neither the Company nor its Board of Directors has made or will make any recommendation to holders regarding the exercise of subscriptions. Holders should make an independent investment decision about whether or not to exercise their subscriptions based on their own assessment of the Company’s business and the Rights Offering.

A registration statement (Registration No. 333-292085) relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The Rights Offering, which is expected to commence following the effectiveness of the registration statement, is being made only by means of a written prospectus. A preliminary prospectus relating to and describing the proposed terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC’s website at View Source Copies of the preliminary and final prospectuses for the Rights Offering may be obtained, when available, from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, Attention Syndicate Department, email: [email protected] or telephone (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Maxim Group LLC is acting as the dealer-manager in connection with the Rights Offering.

(Press release, AIM ImmunoTech, JAN 27, 2026, View Source [SID1234662284])

On January 27, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, reported a strategic partnership on innovative drug development, leveraging Insilico’s proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to the agreement, Insilico Medicine will utilize its proprietary Pharma.AI platform to focus on the design and optimization of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialization procedures. The total contract value approaches $120 million, including development and commercialization milestone payments, as well as single-digit royalties based on net sales.

Weikang Tao, PhD, Board Member, Group VP & Head of Global R&D, Qilu Pharmaceutical Group said, "As a leading pharmaceutical company in China, Qilu has always attached great importance to the quick advancement of AI technology, in particular, the application of AI in drug R&D and its potential. Insilico is a well-known biotech in AI-powered drug R&D with advanced AI technology and application capabilities. This collaboration marks a deepening of our partnership, evolving from initial software licensing to in-depth, R&D collaboration. We look forward to the smooth progress of this innovative drug discovery and development project through the synergy of Qilu’s extensive R&D experience and capabilities and Insilico’s advanced AI platform and expertise, thereby to address unmet medical needs and to bring new hope to patients worldwide."

Alex Zhavoronkov, PhD, Founder and Chief Executive Officer, Chief Business Officer of Insilico Medicine said, "We are pleased to see Insilico Medicine and Qilu Pharmaceutical further deepen their strategic collaboration driven by generative AI. Recently, Insilico Medicine unveiled its proprietary cardiometabolic portfolio at the BIO-Europe conference, covering 8 drug candidates ranging from hit to IND-enabling stage, all driven by Pharma.AI in their development process. I believe that strategies targeting cardiometabolic diseases have the potential to generate the first drugs to achieve large-scale healthspan extension, and I look forward to AI technology accelerating innovation in the field and maximizing potential."

Based on drug discovery and development, software solution licensing, and innovative expansion beyond drug development, Insilico Medicine continues to validate its diversified business model, securing software licensing agreements with 13 of the world’s top 20 multinational pharmaceutical companies, establishing research collaborations with upfront payments of tens of millions of dollars with Fosun Pharma and Sanofi; and reaching pipeline out-licensing deals with Exelixis and Menarini Group, with total transaction values exceeding $2 billion. Notably, Qilu Pharmaceutical first started using PandaOmics in 2021, thus leading to the near $120 million collaboration today, which will further deepen the empowering role of the artificial intelligence platform and drive innovative therapy development with even higher efficiency.

In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry, medicine development and science research. Powered by Pharma.AI, Insilico has nominated 22 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of over 30 assets since 2021, with the most advanced candidate Rentosertib achieving positive results in Phase IIa clinical trials, achieving the first proof-of-concept for AI-driven drug development in the clinical stage.

(Press release, Insilico Medicine, JAN 27, 2026, https://www.prnewswire.com/news-releases/insilico-medicine-and-qilu-pharmaceutical-reach-near-120-million-drug-development-collaboration-to-accelerate-novel-cardiometabolic-therapies-302671276.html [SID1234662303])

On January 27, 2026 Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, reported a license and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody from Simcere, for the treatment of inflammatory bowel disease (IBD).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Globally, it is estimated that more than three million people are affected by IBD, a lifelong, progressive condition leading to frequent hospitalization and surgeries, significantly impacting patients’ quality of life. Current medical options cannot fully prevent or reverse these complications, leaving a clear unmet need. Through this partnership, Boehringer and Simcere aim to advance an innovative approach to potentially redefine treatment possibilities and improve outcomes for patients worldwide.

SIM0709 is a long-acting humanized bispecific antibody developed by Simcere using its proprietary multi-specific antibody platform. It simultaneously targets tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), thereby blocking two core pathways that drive the onset and progression of IBD. Both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, even outperforming the combination of the two corresponding monotherapies.

Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim said, "In IBD, too many patients continue to progress and experience severe complications despite currently available anti-inflammatory therapies. We are excited to join forces with Simcere to accelerate the development of this therapeutic as a potential life changing option for patients living with IBD."

"Simcere’s bispecific antibody SIM0709 was engineered with our proprietary multi-specific antibody platform with first-in-class potential for IBD treatment. Partnering with Boehringer Ingelheim, with its long‑term commitment and deep expertise in immunology, positions the compound for rigorous global development," said Gaobo Zhou, Chief Investment Officer, Simcere Pharmaceutical Group. "Together we aim to accelerate the clinical development and advance a treatment option that could improve outcomes for patients world-wide affected by IBD."

Under the terms of the agreement Boehringer receives global rights to the asset, excluding greater China. Simcere is eligible to receive an upfront payment as well as success-based development, regulatory and sales milestones up to EUR 1,058 million, as well as royalties on net sales outside of the Greater China territory.

This marks Simcere’s second out- licensing transaction in the autoimmune field. As of January 2026, Simcere has completed a total of 5 out-licensing deals for its self-developed novel drug technologies, with a total potential transaction value of approximately $4.6 billion.

(Press release, Boehringer Ingelheim, JAN 27, 2026, View Source [SID1234662304])

On January 27, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported a leadership transition designed to support the Company’s next phase of growth and advancement toward late-stage development and key clinical and corporate milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mani Mohindru, PhD, a member of Cardiff Oncology’s Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their respective roles.

As part of this transition, Ms. Brigitte Lindsay has been promoted to the role of Chief Accounting Officer, ensuring continuity within the finance function. She has been with the Company for more than 14 years and was most recently the Senior Vice President of Finance. The Company has initiated a search for a permanent Chief Executive Officer and Chief Financial Officer.

Cardiff Oncology’s lead product candidate, onvansertib, a highly specific, oral PLK1 inhibitor, is currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer (mCRC) and is also being evaluated as a single agent and in combinations across multiple additional cancers in investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia. The leadership transition reflects the Company’s focus on execution and clinical advancement as its programs mature.

"As Cardiff Oncology prepares for the next stage of clinical and corporate development, the Board concluded that this was the right moment to align executive and financial leadership with the Company’s evolving needs," said Rodney S. Markin, MD, PhD, Chairman of the Board. "We want to express our sincere gratitude to Mark and Jamie for their significant contributions in guiding Cardiff to where it stands today—especially in the progress of our lead product candidate in first-line RAS-mutated mCRC, an area of high unmet need where there have not been any significant advancements in many years. Looking forward, we are confident in Dr. Mohindru’s ability to lead the Company at this key moment in onvansertib’s clinical development, as she brings a rare combination of deep scientific training, operational leadership, and capital markets expertise."

"Cardiff Oncology has built a strong scientific and clinical foundation around PLK1 inhibition, with onvansertib demonstrating encouraging activity in a challenging to treat patient population," said Mani Mohindru, PhD, interim Chief Executive Officer. "Given onvansertib’s activity in RAS-mutated mCRC as well as encouraging single agent data, there is potential to extend its benefit to other solid tumors and hematologic malignancies. I look forward to working closely with the Board and the team to sharpen our strategic priorities, advance our clinical programs, and thoughtfully position the Company for late-stage development while maintaining a disciplined approach to capital and execution."

Dr. Mohindru is an experienced biotechnology executive with leadership experience spanning drug development, corporate strategy, and capital markets. She is the founder of Roshon Therapeutics, a private biotechnology company focused on developing novel therapies for cancer and inflammatory diseases, and currently serves on the Board of Directors of CytomX Therapeutics, Inc. (Nasdaq: CTMX). Previously, Dr. Mohindru served as Chief Executive Officer and Board Director of Novasenta and CereXis, and held senior leadership roles at public biotechnology companies including Cara Therapeutics, Inc. and Curis, Inc.

Earlier in her career, Dr. Mohindru was an equity research analyst covering the biotechnology sector at UBS, Credit Suisse, and ThinkEquity. She currently serves on the Executive Advisory Board of the CLP Institute at Northwestern University and the Scientific Investment Advisory Committee of the Gates Institute at the University of Colorado. Dr. Mohindru holds a PhD in Neurosciences from Northwestern University, as well as a BS in Human Biology and a Master’s degree in Biotechnology from the All India Institute of Medical Sciences in New Delhi, India.

(Press release, Cardiff Oncology, JAN 27, 2026, View Source [SID1234662287])